Posters/Exhibits/Break > Session
Posters/Exhibits/Break
Presentations
A1. ANTICOAGULATION CLINICS | |||||
|
(301) NOVEL POINT-OF-CARE (POC) PLATFORM FOR DIRECT ORAL ANTICOAGULANTS (DOAC) AND VITAMIN K ANTAGONISTS (AVK) TESTING: MICRODOAC AND MICROINR ASSAYS Tamara Montes, Mikel Santiago, Irene Mijangos. R&D Department, iLine Microsystems S.L., San Sebastián/Donostia, Spain |
||||
A2. PLATELET ACTIVATION AND BIOCHEMISTRY | |||||
|
(302) RED BLOOD CELL HAEMOLYSIS AND PLATELET ACTIVATION : THE FORGOTTEN PLAYERS OF HYPERCOAGULABILITY Neha Thomas, Stipo Jurcevic. University of Westminster, London, United Kingdom |
||||
A4. DISORDERS OF PLATELET NUMBER OR FUNCTION | |||||
|
(303) HMB-001 FOR PROPHYLACTIC TREATMENT OF GLANZMANN THROMBASTHENIA: PHASE 1/2 TRIAL INSIGHTS Suthesh Sivapalaratnam1,2, Gillian Lowe3, Ashley Gosnell4, Ulrike Lorch5, Jigar Amin4, Catherine Rea4. 1Queen Mary University of London, London, United Kingdom 2Barts Health NHS Trust, London, United Kingdom 3Comprehensive Care Haemophilia Centre, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom 4Hemab Therapeutics, Cambridge, MA, USA 5Richmond Pharmacology, London, United Kingdom |
||||
A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS | |||||
|
(304) INVESTIGATING THE RELATIONSHIP BETWEEN D DIMER LEVELS AND VISCOELASTIC CHARACTERISTICS OF BLOOD CLOTS Eli J Foster, Nathaniel Hai, Seemantini K Nadkarni. Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA |
||||
|
(305) TRANSFUSION TRENDS IN THE OBSTETRIC POPULATION WITH ANALYSIS OF A SOFT STOP TRANSFUSION EMR ALERT Maren Plant1, Sophia Cordes1, Caroline Bereuter1, Jaclyn Phillips1, Xiomara Fernandez2, Homa Ahmadzia1. 1Department of Obstetrics and Gynecology, George Washington University, Washington, DC, USA 2Department of Pathology, George Washington University, Washington, DC, USA |
||||
A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS | |||||
|
(306) THE BURDEN OF HEMOPHILIA IN THE US: METHODS AND RESULTS FROM THE COST OF HEMOPHILIA: A SOCIOECONOMIC SURVEY (CHESS) US (2022) Randall Curtis1, Maria Elisa Mancuso2,3, Enrico Ferri Grazzi4, Donna Coffin5, Brian O'Mahony6,7, Clive Smith8, Daniél Anibal García Diego9, Matteo Arzenton10, Thomas Sannié11, Fiona Brennan12, Tom Burke4,13, Sarah Brighton4. 1Hematology Utilization Group Study (HUGS), Walnut Creek, CA, USA 2Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Italy 3Humanitas University, Pieve Emanuele, Milan, Italy 4HCD Economics, Knutsford, United Kingdom 5World Federation of Hemophilia, Montreal, QC, Canada 6Irish Haemophilia Society Ltd, Dublin, Ireland 7Trinity College, Dublin, Ireland 8The Haemophilia Society, London, United Kingdom 9Federación Española de Hemofilia (FedHemo), Madrid, Spain 10Italian Federation of Haemophilia Associations (FedEmo), Rome, Italy 11Association Française des Hémophiles (AFH), Paris, France 12Faculty of Health and Social Care, University of Chester, Chester, United Kingdom |
||||
|
(307) HEMOSTATIC OUTCOME OF SURGICAL PROCEDURES IN PATIENTS WITH HEMOPHILIA RECEIVING CONCIZUMAB PROPHYLAXIS: DATA FROM THE PHASE 3 EXPLORER7 AND EXPLORER8 TRIALS Matthew Evans1, Anthony K.C. Chan2, Chris Barnes3, Mary Mathias4, Silvia Linari5, Francisco-José López-Jaime6, Lone Hvitfeldt Poulsen7, Julien Bovet8, Jan Odgaard-Jensen8, Tadashi Matsushita9, Emily K. Waters10. 1Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA 2McMaster Children’s Hospital, McMaster Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada 3Royal Children’s Hospital Melbourne, Victoria, Australia 4Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom 5Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy 6Hospital Regional Universitario de Málaga, Málaga, Spain 7The Haemophilia Centre, Department of Haematology, Aarhus University Hospital, Aarhus, Denmark 8Novo Nordisk A/S, Søborg, Denmark 9Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan 10Novo Nordisk Inc., Plainsboro, NJ, USA |
||||
|
(308) ATHN TRANSCENDS - HEMOPHILIA GENE THERAPY OUTCOMES ARM: A LONG-TERM FOLLOW-UP STUDY ON SAFETY AND EFFECTIVENESS OF GENE THERAPY IN PEOPLE WITH HEMOPHILIA Staber Janice1, Blanca Salazar2, Roberto Guillen-Gonzalez2, Michael Recht3,4, Tammuella Chrisentery-Singleton5, Ulrike Reiss6. 1Iowa Hemophilia and Thrombosis Center University of Iowa Stead Family Children’s Hospital, Iowa City, IA, USA 2CSL Behring, King of Prussia, PA, USA 3National Bleeding Disorders Foundation, New York, NY, USA 4Yale University School of Medicine, New Haven, CT, USA 5American Thrombosis and Hemostasis Network, Rochester, NY, USA 6Hemophilia Treatment Center St. Jude’s Children’s Research Hospital, Memphis, TN, USA |
||||
|
(309) A PHASE 3, RANDOMIZED, ACTIVE-CONTROL STUDY OF FOUR-FACTOR PROTHROMBIN COMPLEX CONCENTRATE VERSUS FROZEN PLASMA IN BLEEDING ADULT CARDIAC SURGERY PATIENTS Keyvan Karkouti1,2, Jeannie Callum3,4, Kenichi Tanaka5, Deep Grewal2, Cristina Solomon6, Sigurd Knaub6, Sylvia Werner7, Gita Pezeshki7, Jerrold H. Levy8. 1University of Toronto, Toronto, ON, Canada 2University Health Network, Toronto, ON, Canada 3Queen’s University, Kingston, ON, Canada 4Kingston Health Sciences Centre, Kingston, ON, Canada 5University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA 6Octapharma AG, Lachen, Switzerland 7Octapharma USA, Paramus, NJ, USA 8Duke University School of Medicine, Durham, NC, USA |
||||
|
(310) VITAMIN D DEFICIENCY IN PERSONS WITH BLEEDING DISORDERS - A SINGLE CENTER EXPERIENCE Dan Leary, Mindy Simpson, Lisa Boggio. Rush Hemophilia and Thrombophilia Center, Chicago, IL, USA |
||||
|
(311) GENOMIC VARIATIONS IN FACTOR VII DEFICIENCY PREDISPOSING TO THROMBOPHILIA: A CASE OF SINUS VENOUS THROMBOSIS IN A PATIENT WITH FACTOR VII DEFICIENCY Aaron C. Lobo 1, Paridhi Ghai1, Fabricio M Webber1, David H. Witt2. 1Bridgeport Hospital/Yale New Haven Health, Bridgeport, CT, USA 2Yale Smilow Cancer Center/Yale school of Medicine, Trumbull, CT, USA |
||||
|
(312) EMICIZUMAB PROPHYLAXIS FOR THE TREATMENT OF INFANTS WITH SEVERE HAEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS: PRIMARY ANALYSIS OF THE HAVEN 7 STUDY Steven W. Pipe1, Peter Collins2, Christophe Dhalluin3, Gili Kenet4, 5, Christophe Schmitt3, Muriel Buri3, Víctor Jiménez-Yuste6, Flora Peyvandi7, 8, Guy Young9, Johannes Oldenburg10, Maria Elisa Mancuso11, 12, Kaan Kavakli13, Anna Kiialainen3, Markus Niggli3, Tiffany Chang14, Michaela Lehle 3, Karin Fijnvandraat15. 1University of Michigan, Ann Arbor, MI, USA 2School of Medicine, Cardiff University, Cardiff, United Kingdom 3F. Hoffmann-La Roche Ltd, Basel, Switzerland 4Sheba Medical Center, Ramat Gan, Israel 5Tel Aviv University, Tel Aviv, Israel 6Hospital Universitario La Paz-IdiPaz, Universidad Autónoma, Madrid, Spain 7Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy 8Università degli Studi di Milano, Milan, Italy 9Children’s Hospital Los Angeles, Los Angeles, CA, USA 10Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany 11IRCCS Humanitas Research Hospital, Rozzano, Italy 12Humanitas University, Pieve Emanuele, Milan, Italy 13Ege University Faculty of Medicine Children's Hospital, Izmir, Turkey 14Spark Therapeutics, Inc., San Francisco, CA, USA 15University of Amsterdam, Amsterdam, Netherlands |
||||
|
(313) A MULTI-YEAR FOLLOW-UP STUDY OF FIDANACOGENE ELAPARVOVEC GENE THERAPY FOR HEMOPHILIA B Benjamin J. Samelson-Jones1,2, Lindsey A. George1,2, John E. J. Rasko3,4, Adam Giermasz5, Jerome M. Teitel6, Catherine E. McGuinn7, Jonathan M. Ducore5, Sharon Pennington8, Katherine A. High2, Jeremy Rupon9, Francesca Biondo10, Annie Fang11, Lynne M. Smith9, Matko Kalac11, Amit Chhabra11, Frank Plonski9. 1Children’s Hospital of Philadelphia, Philadelphia, PA, USA 2Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA 3Department of Cell and Molecular Therapies, Royal Prince Alfred Hospital, Sydney, Australia 4Gene and Stem Cell Therapy Program, Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia 5Hemophilia Treatment Center, University of California Davis, Sacramento, CA, USA 6St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada 7Weill Cornell Medicine, New York, NY, USA 8Mississippi Center for Advanced Medicine, Madison, MS, USA 9Pfizer Inc, Collegeville, PA, USA 10Pfizer Srl, Rome, Italy 11Pfizer Inc, New York, NY, USA |
||||
|
(314) EMERGENCY DEPARTMENT UTILIZATION IN A PATIENT COHORT WITH HEMOPHILIA: A SINGLE CENTRE EXPERIENCE Kelsey Uminski1,2, Natalia Rydz1,2, Dawn Goodyear1,2. 1Division of Hematology and Hematological Malignancies, Department of Medicine, University of Calgary, Calgary, AB, Canada 2Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, Calgary, AB, Canada |
||||
A8. ANTITHROMBOTIC THERAPY | |||||
|
(315) DUAL DIRECT ORAL ANTICOAGULANT THERAPY IN CHALLENGING THROMBOSIS: A CASE SERIES Heather McPhaden1, Chornenki Nicholas1, Peterson Erica1, Lai Chieh Min Benjamin1,2, Lee Agnes1. 1The University of British Columbia, Department of Medicine, Division of Hematology, Vancouver, BC, Canada 2The University of British Columbia Centre for Blood Research, Vancouver, BC, Canada |
||||
|
(316) RECURRENT VENOUS THROMBOEMBOLISM IN A SYMPTOMATIC HEMOPHILIA A CARRIER Natalie/A Montanez1,3, Joanna/M Larson1,3, Miguel/A Escobar1,2,3. 1University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics, Houston, TX, USA 2University of Texas Health Science Center of Houston, McGovern Medical School, Department of Internal Medicine, Houston, TX, USA 3Gulf States Hemophilia and Thrombophilia Center, Houston, TX, USA |
||||
|
(317) A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF HUMAN PLASMA DERIVED ANTITHROMBIN (ATENATIV) IN HEPARIN-RESISTANT CARDIAC SURGERY PATIENTS Cristina Solomon1, Catrin Argyle1, Jerrold H. Levy2, Sylvia Werner1. 1Octapharma AG, Lachen, Switzerland 2Duke University School of Medicine, Durham, NC, USA |
||||
|
(318) AN IMPLEMENTATION DILEMMA: REJECTION OF THROMBOPROPHYLAXIS RECOMMENDATIONS IN THE CHILDREN'S LIKELIHOOD OF THROMBOSIS (CLOT) TRIAL Shannon C. Walker, Benjamin French, Ryan P. Moore, Henry J. Domenico, C. Buddy Creech, Amanda S. Mixon, Daniel W. Byrne, Allison P. Wheeler. Vanderbilt University Medical Center, Nashville, TN, USA |
||||
A9. INFORMATIONAL ABSTRACT (POSTER ONLY) | |||||
|
(319) OVERCOMING DISTANCE AND TRAVEL BARRIERS FOR VIRGINIA BLEEDING DISORDERS TREATMENT CENTERS: A COMPREHENSIVE NEEDS ASSESSMENT Erika J Martin, Lauren C Dunn, Katherine L Bains, Janice G Kuhn. Virginia Commonwealth University, Richmond, VA, USA |
||||
|
(320) DOAC'S IN THE ELDERLY Abhinav Paknikar1, Keerti Chakravarthy1, Fakiha Siddiqui2, Atul Laddu1, Jawed Fareed2, Aarushi Dua1, Anish Joshi1. 1Global Thrombosis Forum, Suwanee, GA, USA 2Loyola University, Chicago, IL, USA |
||||